Dr Reddy's unit ties up with Shanghai Henlius Biotech

Dr Reddy's Laboratories has partnered with Shanghai Henlius Biotech to develop and commercialize HLX15, a biosimilar to the cancer drug Darzalex. Henlius will manage development and manufacturing, receiving up to $131.6 million. Dr Reddy's gains exclusive rights to market the drug in the US and Europe.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/0IXQqVc
via IFTTT